Neoplasms

Skin and Connective Tissue Diseases

All Conditions

Digestive System Diseases

Symptoms and General Pathology

Breast Neoplasms

Liver Cirrhosis

Fibrosis

Liver Diseases

Gastrointestinal Diseases

Hypoglycemic Agents

All Drugs and Chemicals

Anti-Arrhythmia Agents

Cardiotonic Agents

Lipid Regulating Agents

Natriuretic Agents

Hematinics

Anti-Infective Agents

Antineoplastic Agents

Bone Density Conservation Agents

Metformin

Digoxin

Rosuvastatin Calcium

Furosemide

Liver Extracts

polysaccharide-K

Calcium

Calcium, Dietary

Anticholesteremic Agents

Hypolipidemic Agents

Antimetabolites

Hydroxymethylglutaryl-CoA Reductase Inhibitors

Enzyme Inhibitors

Diuretics

Sodium Potassium Chloride Symporter Inhibitors

Protective Agents

Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.

Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.

Compensated=without any disease symptoms

Every participant receives a cocktail of Rosuvastatin, Digoxin, Metformin hydrochlorid, Furosemide.

Decompensated= with disease symptoms like aszites, variceal bleeding, hepatic encephalopathy, hepato-renal syndrome

Rosuvastatin

Metformin hydrochlorid

Boehringer Ingelheim

The main trial objective, is to ascertain whether the transport activity, given by the maximum concentration (Cmax) and the area under the curve (AUC0-24) values for the different components in the transporter cocktail are similar or different in F4 liver cirrhosis patients on standard therapy compared to healthy subjects.

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Transporter Profiling Study for P-glycoprotein 1 (P-gp), Organic Anion Transporter 1 (OAT1), Organic Anion Transporter 3 (OAT3), Organic Cation Transporter 2 (OCT2), Multidrug and Toxin Extrusion Protein 1 (MATE1), Multidrug and Toxin Extrusion Protein 2-K (MATE2-K), Organic Anion Transporting Polypeptide 1B1 (OATP1B1), Organic Anion Transporting Polypeptide 1B3 (OATP1B3) and Breast Cancer Resistance Protein (BCRP) in Healthy Subjects and in Patients With Stage 4 (F4) Liver Fibrosis / Cirrhosis.

Clinical studies sponsored by Boehringer Ingelheim, phases I to IV, interventional and non-interventional, are in scope for sharing of the raw clinical study data and clinical study documents. Exceptions might apply, e.g., studies in products where Boehringer Ingelheim is not the license holder; studies regarding pharmaceutical formulations and associated analytical methods, and studies pertinent to pharmacokinetics using human biomaterials; studies conducted in a single center or targeting rare diseases (in case of low number of patients and therefore limitations with anonymization). For more details refer to: https:// www.mystudywindow.com/msw/datatransparency

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization	Link
A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis	NCT05741372	Liver Cirrhosis	Rosuvastatin Digoxin Metformin hydro... Furosemide	18 Years - 75 Years	Boehringer Ingelheim
A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis	NCT05741372	Liver Cirrhosis	Rosuvastatin Digoxin Metformin hydro... Furosemide	18 Years - 75 Years	Boehringer Ingelheim

Spots Global Cancer Trial Database for metformin hydrochlorid